Xeltis has raised a $33M Series D extension funding round to revolutionize cardiovascular recovery by helping the body create new vessels.
Since its inception in 2006, the company has raised over $120M.
- Xeltis is a medical technology company that aims to modernize cardiovascular disease treatment by helping the body create new vessels and valves.
- The company is currently working on three products:
- pulmonary heart valves,
- coronary artery bypass grafts,
- and hemodialysis access grafts.
- The company aims to focus on China, as the country has the world's largest number of patients with chronic kidney diseases, a health field Xeltis is researching intensively.
- Grand Pharma led the funding round, with participation from DaVita Venture Group, EQT Life Sciences, and Invest-NL.
- The company is based in Eindhoven, Netherlands.